FDA Inspection Update: The FDA’s rigorous inspection regime has recently brought several key developments to the forefront. Lupin Limited’s Mandideep Unit-2 facility has successfully navigated an FDA inspection, securing the company’s ability to continue its supply of generic medications to the U.S. market. This approval is particularly crucial for Lupin, as the U.S. represents its largest consumer base. In another significant development, Amgen’s Wezlana, a … Continue reading FDA Inspection Update: Lupin’s Mandideep Facility Clears US FDA Audit, Amgen’s New Biosimilar Wins Approval